DRUG DISCOVERY AND GENOMIC TECHNOLOGIES
The very nature of genome research demands regular improvement and development of innovative molecular tools and technologies for biotechnological and therapeutic applications. Current bacterial artificial chromosome (BAC) vector technology has enabled the construction of BAC libraries from a large number of species, including the human RPCI-11 and the mouse RPCI-23 libraries, which were used in the corresponding public sequencing genome projects. Such libraries are invaluable for an initial understanding of the genome sequence and structure of each organism and for the isolation of clones carrying most genomic loci as intact functional units. However, the majority of these libraries were made in BAC cloning vectors that do not facilitate functional studies in eukaryotic cells. To overcome this limitation, retrofitting genomic inserts as NotI fragments into novel BAC vectors has been reported (1-3). Retrofitting strategies based on targeting the insertion of a variety of cassettes into the loxP site of P1 artificial chromosome (PAC) and BAC vectors by Cre recombinase have also been reported (4-6). Such site-specific modifications invariably depend on the insertion of a second antibiotic selection marker on the vector backbone. They also require the prior removal or inactivation of multicopy origins of replication on the retrofitting plasmids and are limited to sequences recognized by Cre recombinase. It is, therefore, not possible with these approaches to transfer genomic inserts from first generation PAC or BAC vectors into novel BAC vectors that are optimized for functional studies in yeast and higher organisms.
We have recently developed pEBAC190G (3), an enhanced BAC vector that combines the essential features of the first generation PAC/BAC vectors (7, 8) with eukaryotic elements that facilitate the transfection, episomal maintenance, and functional analysis of large genomic fragments in eukaryotic cells (9) . This vector was developed primarily for the creation of new "functional" BAC libraries. However, a major barrier for the construction of novel BAC libraries is the considerable expenditure and resources required. Additionally, there are clear advantages in performing functional studies on sequenced BAC clones from the Human Genome Project rather than on new clones from functional BAC libraries, since any clones in the 100-300 kb range are likely to have a few hundred sequence polymorphisms with unpredictable consequences on the regulation of gene expression. The pEBAC190G vector greatly facilitates the retrofitting of genomic inserts from existing BAC libraries as NotI fragments by positive sucrose selection of recombinants (3) . On the other hand, many genomic inserts in BAC clones have internal NotI sites and cannot be transferred intact to novel BAC vectors by NotI restriction digestion and ligation. Clearly, such hurdles can be overcome by partial digestion or the engineering of custom-made linkers/ adaptors for the creation of compatible sites, but such procedures can be timeconsuming.
In order to facilitate maximal use of sequenced PAC/BAC clones from the human and other genome projects, we have therefore devised a simple but effective strategy to transfer large DNA fragments from existing PAC/ BAC vectors into our pEBAC vectors by way of vector exchange using homologous recombination. Here we demonstrate this approach for BAC clones made with the pBACe3.6 vector (10). This was achieved by exploiting the sequence homology that exists between pEBAC190G and pBACe3.6 vectors at both ends of the cloning region. The homology at one end extends over the whole length of the sacB gene (1419 bp), while at the other end, it encompasses 41 bp of the sacB promoter. Because both these vectors are chloramphenicol-resistant, this strategy also necessitated the replacement of the chloramphenicol cassette in pEBAC190G with kanamycin. Briefly, a 918-bp fragment encoding the kanamycin resistance gene was amplified from plasmid pCYPAC2 (7) with primers KANF 5′-CGGGCGTATTTTTTGAGT-TATCGAGATTTTCAGGAGCTA-AGGAAGCTAAAA TGAGCCA-TATTCAACGGGAAAC-3′ and KANR 5′-CAGGCGTAGCAACCAGGCGTT-TAAGGGCACCAATAACTGCCT-TA A A A A A A T TAG A A A A AC T-CATCGAGCATC-3′. Each primer has 51 bp at the 5′ end (bolded) that is homologous to sequences flanking the chloramphenicol cassette in pEBAC190G, while the sequences that are unbolded correspond to primer sequences at the 5′ and 3′ ends of the kanamycin resistance gene. About 100 ng of the PCR product was electroporated into recombination-proficient DY380 cells (11) containing pEBAC190G, followed by selection on kanamycin/ ampicillin plates. The resulting BAC vector, pEBAC200G (Figure 1) was readily isolated and shown to have the expected structure without any other modifications or rearrangements (data not shown).
To demonstrate the utility of the pEBAC200G vector in our vector exchange protocol, we chose to transfer a 188-kb genomic fragment from a BAC clone (pBAC/265) that harbors the human FRDA locus in the pBACe3.6 vector (12) . This clone contains an internal NotI site in exon I of the FRDA locus, thus preventing its transfer as a single fragment into the pEBAC190G vector for functional studies. Preparation of the pEBAC200G vector involved the removal of the pUC-stuffer fragment by digestion with both BamHI and NotI enzymes, to reduce background 
Clones generated by recombination between the linearized pEBAC200G vector and homologous sequences on the pBACe3.6 vector domain of pBAC/265 were readily identified and confirmed by pulsed field gel electrophoresis after digestion with NotI. Correct recombinant clones showed the expected shift in the length of the vector backbone from 8.7 kb in pBAC/265 (Figure 2, lane 1 Since pEBAC200G has a number of regions on the vector backbone that are identical with sequences in pBACe3.6, it is likely that clones with intermediate size vector fragments arise through recombination in internal homology regions. About 70% of the clones appeared to be false recombinants with no detectable change in the size of the vector fragment, yet extraction and re-electroporation of BAC DNA into DH10B cells showed that at least some of these clones had acquired kanamycin resistance. Such clones may arise through recombination between homologous sequences immediately flanking the chloramphenicol and kanamycin genes in the pBACe3.6 and pEBAC200G vectors, respectively. This approach should also be applicable to clones from BAC libraries made with the pTARBAC derivatives of the pBACe3.6 vector (http:// bacpac.chori.org/vectorsdet.htm), since the terminal homology elements that facilitate vector exchange between pBACe3.6 and pEBAC200G are also maintained in these vectors. Vector exchange with PAC clones (kanamycinresistant) should also be possible with this approach using the pEBAC190G vector to provide selection of recombinant clones on chloramphenicol. Similar approaches may be readily adapted for the retrofitting of clones from BAC libraries made with the pBeloBAC11 vector (8) .
In this work we have used the homologous recombination system in DY380 (11) to facilitate vector exchange. We anticipate that the GET Recombination system (2,13) should also be suitable for such studies, thus obviating the need to transfer BAC clones from DH10B to DY380 cells.
In conclusion, we have developed a vector exchange approach for the convenient transfer of large genomic DNA fragments from PAC/BAC libraries made with the first generation PAC or BAC vectors into enhanced eukaryotic BAC vectors. Our strategy enables the extensive redesign and development of BAC vectors without any of the obvious limitations and restrictions of approaches that are based on site-specific recombination or the retrofitting of restriction fragments. This will greatly facilitate the incorporation of eukaryotic elements into PAC and BAC clones for functional studies and therapeutic applications.
